Amid soaring demand and shortages of highly popular GLP-1 (glucagon-like peptide-1 receptor agonists) medications for weight loss, digital health platforms have become an alternate and more affordable source of the drugs for consumers
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M
Most studies evaluating BPC-157, thymosin beta-4 derivatives, and related peptide agents are preclinical, employ heterogeneous dosing regimens, and report surrogate endpoints that do not translate directly to operative recovery or implant-based outcomes
10.1371/journal.pone.0049121 39 HanV
Please raise your hand
(2024) 19:e0306572